February 20, 2024
1 min watch
Save
VIDEO: Study probes lebrikizumab for atopic dermatitis patients with skin of color
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-13 blocker lebrikizumab from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed studies looking at elderly patients and a phase 3B study looking at patients with skin of color.
“It’s a very early interim analysis, but one of the best examples we have of taking a look at diverse populations with atopic dermatitis in a systemic study,” Chovatiya said.